##### Table of Contents



UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549
 Form 10-K/A
 (Amendment No. 1)
 þ
    
    ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 For the fiscal year ended September 30, 2008
 OR
 o
    
    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 For the transition period from            to
 Commission File No. 1-15803
 Avanir Pharmaceuticals
 (Exact name of registrant as specified in its charter)
 California
    
    33-0314804(State or other jurisdiction of
    
    (I.R.S. Employer Identification No.)incorporation or organization)101 Enterprise Suite 300,
    
    92656Aliso Viejo, California
    
    (Zip Code)(Address of principal executive offices)
 (949) 389-6700  (Registrants telephone number, including area code)
 Securities registered pursuant to Section 12(b) of the Act:
 Title of each class
    
    Name of each exchange on which registeredClass A Common Stock, no par value
    
    The NASDAQ Stock Market LLC
 Securities registered pursuant to Section 12(g) of the Act: None
 o þ
 o þ
 þ o
 o
  Large accelerated filer o
    
    Accelerated filer o
    
    Non-accelerated filer o
    
    Smaller reporting company þ(Do not check if a smaller reporting company)
 o þ




---



TABLE OF CONTENTS  Item 9A. Controls and ProceduresItem 15. Exhibits and Financial Statement SchedulesSIGNATURESEX-31.1EX-31.2EX-32.1EX-32.2    Table of Contents  Explanatory Note
  
 Item 9A. Controls and Procedures
 Evaluation of Disclosure Controls and Procedures
   Managements Report on Internal Control Over Financial Reporting
 Internal Control  Integrated
Framework
  Changes in Internal Control over Financial Reporting




---



##### Table of Contents



Item 15. Exhibits and Financial Statement Schedules
  Exhibit No.
    
    Description31.1
    
    Certification of Principal Executive Officer pursuant to Section 302 of Sarbanes-Oxley Act of 200231.2
    
    Certification of Principal Financial Officer pursuant to Section 302 of Sarbanes-Oxley Act of 200232.1
    
    Certification of Principal Executive Officer pursuant to Section 906 of Sarbanes-Oxley Act of 200232.2
    
    Certification of Principal Financial Officer pursuant to Section 906 of Sarbanes-Oxley Act of 2002




---



##### Table of Contents



SIGNATURES
  Avanir PharmaceuticalsBy:

/s/ Keith A. KatkinKeith A. KatkinPresident and Chief Executive Officer   Signature
    
    Title
    
    Date/s/ Keith A. Katkin
    
    President and Chief Executive Officer
    
    December 24, 2008Keith A. Katkin
    
    (Principal Executive Officer)/s/ Christine G. Ocampo
    
    Vice President, Finance
    
    December 24, 2008Christine G. Ocampo
    
    (Principal Financial Officer)/s/ Craig A. WheelerCraig A. Wheeler
    
    Director, Chairman of the Board
    
    December 24, 2008/s/ Stephen G. Austin, CPAStephen G. Austin, CPA
    
    Director
    
    December 24, 2008/s/ Charles A. MathewsCharles A. Mathews
    
    Director
    
    December 24, 2008/s/ David J. Mazzo, Ph.D.David J. Mazzo, Ph.D.
    
    Director
    
    December 24, 2008Dennis G. Podlesak
    
    Director
    
    December 24, 2008/s/ Nicholas J. SimonNicholas J. Simon
    
    Director
    
    December 24, 2008/s/ Scott M. Whitcup, M.D.Scott M. Whitcup, M.D.
    
    Director
    
    December 24, 2008